Time to first treatment and P53 dysfunction in chronic lymphocytic leukaemia: results of the O-CLL1 study in early stage patients

Chronic lymphocytic leukaemia (CLL) is characterised by a heterogeneous clinical course. Such heterogeneity is associated with a number of markers, including TP53 gene inactivation. While TP53 gene alterations determine resistance to chemotherapy, it is not clear whether they can influence early dis...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
הוצא לאור ב:Sci Rep
Main Authors: Monti, Paola, Lionetti, Marta, De Luca, Giuseppa, Menichini, Paola, Recchia, Anna Grazia, Matis, Serena, Colombo, Monica, Fabris, Sonia, Speciale, Andrea, Barbieri, Marzia, Gentile, Massimo, Zupo, Simonetta, Dono, Mariella, Ibatici, Adalberto, Neri, Antonino, Ferrarini, Manlio, Fais, Franco, Fronza, Gilberto, Cutrona, Giovanna, Morabito, Fortunato
פורמט: Artigo
שפה:Inglês
יצא לאור: Nature Publishing Group UK 2020
נושאים:
Article
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC7595214/
https://ncbi.nlm.nih.gov/pubmed/33116240
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41598-020-75364-3
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים